Parenteral versus oral treatment of postmenopausal women with estrogen

Menopause

Volumn 14, Issue 6, 2007, Pages 968-970

  Stanczyk, Frank Z ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG METABOLISM; EDITORIAL; FIBRINOLYSIS; HEMOSTASIS; HORMONAL THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIVER METABOLISM; MENOPAUSAL SYNDROME; PATIENT COMPLIANCE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; POSTMENOPAUSE;

EID: 36049030294     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318157c0c9     Document Type: Editorial

References (27)

1. Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862-867.
2. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;2073:199-208.
3. Shlipak MG, Chaput LA, Vittinghoff E, et al. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J 2003;146:870-875.
4. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
6. Glueck CJ, Scheel D, Fishback J, Steiner P. Estrogen-induced pancreatitis in patients with previously covert familiar type V hyperlipoproteinemia. Metabolism 1972;21:657-666.
7. Koh KK, Yoon B-K, Bairey-Merz CN, Sakuma I, Rebar RW. The effects of hormone therapy on inflammatory, hemostatic and fibrinolytic markers in postmenopausal women. In: Lobo RA ed. Treatment of the Postmenopausal Woman, 3rd ed. Burlington, MA: Academic Press, 2007:471-480.
8. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392-395.
9. Barnes RB, Levrant SG. Pharmacology of estrogens. In: Lobo RA ed. Treatment of the Postmenopausal Woman, 3rd ed. Burlington, MA: Academic Press, 2007:767-777.
10. Slater CC, Hodis HN, Mack WJ, Shoupe D, Paulson RJ, Stanczyk FZ. Markedly elevated levels of estrone sulfate following long-term oral, but not transdermal, administration in postmenopausal women. Menopause 2001;8:200-203.
11. Stanczyk FZ, Chaikittisilpa S, Roy S. Pharmacologic deficiency in Women's Health Initiative study. J Reprod Med 2003;48:485-486. (Letter).
12. Tsujimoto G, Hashimoto K, Hoffman BB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age. Part 1. Int J Clin Pharmacol Ther Toxicol 1989;27:13-26.
13. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331-339.
14. Elkik F, Compel A, Mercier-Bodard C. Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women. Am J Obstet Gynecol 1982;143:888-892.
15. Basdevant A, De Lignieres B, Guy-Grand B. Differential lipemic and hormonal responses to oral and parenteral 17beta-estradiol in postmenopausal women. Am J Obstet Gynecol 1983;147:77-81.
16. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-1620.
17. De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-541.
18. Sattar N, Perera M, Small M, Lumsden MA. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet 1999;354:487-488.
19. Modena MG, Bursi F, Fantini G, et al. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am J Med 2002;113:314-331.
20. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625.
21. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002;106:1224-1228.
22. Koh KK, Bui MN, Mincemoyer R, Cannon RO III. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997;80:1505-1507.
23. Post MS, van der Mooren MJ, van Baal WM, et al. Effects of low-dose and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol 2003;189:1221-1227.
24. Zegura B, Keber I, Sebestjen M, Koenig W. Double blind randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003;168:123-129.
25. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis on postmenopausal women. N Engl J Med 1997;336:683-690.
26. Canonico M, Oger E, Plu-Bureau G, et al. for the Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845.
27. Shifren J, Desindes S, McIlwain M, Doros G, Mazer N. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985-994.